• The epidemiology of the mucambo virus is related to the Venezuelan equine encephalitis virus (VEEV). It is a virus that mosquitoes carry and spread and causes encephalomyelitis, also known as Venezuelan equine encephalitis (VEE), in humans and animals.
• Mucambo virus is a subtype of VEEV and belongs to the antigenic group A. There are also varieties of mucambo virus, such as Tonate virus, which have been classified based on their antigenic differences.
• Mucambo virus has enzootic and epizootic transmission cycles. In the enzootic cycle, the mucambo virus continuously circulates in the tropical woods and mangroves of the Americas, between mosquitoes & wild rodents. Species of wild rodents in the subfamily Sigmodontinae serve as the main reservoirs. But bats can also serve as unintentional reservoirs. of mucambo virus. In the epizootic cycle, mucambo virus can infect equines, such as horses, donkeys, and zebras, where it can cause high mortality and morbidity. Equines can also amplify the virus and facilitate its transmission to humans by mosquito vectors. Dogs, pigs, and cattle are among the other species that might contract the disease, though they often don’t exhibit any symptoms or aid in its spread.
• The geographic distribution of the mucambo virus includes South America and the Caribbean. Mucambo virus has been isolated from Brazil, Colombia, Ecuador, French Guiana, Guyana, Peru, Suriname, Trinidad and Tobago, and Venezuela. The mucambo virus (subtype III) evolved around 1807 AD. With the use of cultivated mosquito cells, José Esparza and J. Sánchez discovered the mucambo subtype in Venezuela in 1975.
• The incidence and prevalence of mucambo virus infection in humans and animals are unknown. However, some outbreaks of VEE have been associated with the mucambo virus or its varieties. For example, in 1995, an outbreak of VEE occurred in Venezuela and Colombia, affecting more than 75,000 people and killing 300. The causative agent was identified as a new mucambo virus named ID. In 2004, another outbreak of VEE occurred in Peru, affecting more than 40 people and killing one. The causative agent was identified as a new variety of Tonate virus named IE. In 2016, a case of VEE was reported by a traveler from French Guiana who visited Suriname. The causative agent was identified as a variety of mucambo viruses named IIIC.
• The risk factors for mucambo virus infection include exposure to mosquito bites in endemic areas, contact with infected animals or their fluids or tissues, and travel to regions where VEE outbreaks have occurred. Preventive and control measures for mucambo virus infection include vector control, animal vaccination, personal protection, surveillance, and public health education. There is no specific antiviral treatment for mucambo virus infection. Supportive care and symptomatic management are the main options for patients. A vaccine for VEE has been used in humans and animals in some countries. However, the vaccine is not widely available or licensed for general use.

• Kingdom: Virus
• Phylum: Kitrinoviricota
• Class: Alsuviricetes
• Order: Martellivirales
• Family: Togaviridae
• Genus: Alphavirus
• Species: Mucambo virus

The structure of the Mucambo virus can be summarized in five points as follows:

• Mucambo virus is a subtype of Venezuelan equine encephalitis virus (VEEV), which is a virus spread by mosquitoes that infect humans and animals and causes Venezuelan equine encephalitis, often known as encephalomyelitis (VEE).
• The genome of the Mucambo virus is a single-stranded positive-sense RNA molecule of about 12 kilobases in length, encoding two polyproteins for the non-structural and structural proteins.
• The capsid of the mucambo virus is two hundred forty copies of the capsid protein (C) that make up the protein shell, forming an icosahedral symmetry with a diameter of about 40 nanometers.
• The envelope of the mucambo virus is a lipid bilayer that is made of the membrane of the host cell, containing 80 spikes composed of heterodimers of the envelope glycoproteins (E1 and E2) and a small protein called 6K.
• The envelope glycoproteins mediate the attachment & the virus’s fusion with the host of the cell membrane. At the same time, the capsid protein interacts with the envelope glycoproteins to form spikes on the virus’s surface.

The antigenic types of mucambo virus are related to the Venezuelan equine encephalitis (VEE) virus, a virus spread by mosquitoes that results in encephalomyelitis or Venezuelan equine encephalitis (VEE)

Mucambo virus is a subtype of VEE virus and belongs to the antigenic group A. There are also varieties of mucambo virus, such as Tonate virus, which have been classified based on their antigenic differences. Antigenic variation is a process by which some microorganisms can change their surface molecules to evade the host’s immune system. Antigenic variation can affect infectious disease diagnosis, treatment, and prevention. Some of the named strains of mucambo virus are:

• Tonate virus: This is a variety of mucambo viruses isolated from Brazil, Colombia, Ecuador, Guyana, French Guiana, Peru, Trinidad & Tobago, Suriname, and Venezuela. Tonate virus has been associated with some outbreaks of VEE in humans and animals.
• ID virus: This is a new variety of mucambo virus identified as the causative agent of a large outbreak of VEE in Venezuela and Colombia in 1995, affecting more than 75,000 people and killing 300. ID virus is highly pathogenic to equines and humans.
• IE virus: This is another new variety of Tonate virus identified as the causative agent of an outbreak of VEE in Peru in 2004, affecting more than 40 people and killing one. IE virus is also highly pathogenic to equines and humans.
• IIIC virus: This is a variety of mucambo virus identified as the causative agent of a case of VEE in a traveler from French Guiana who visited Suriname in 2016. IIIC virus is less pathogenic to equines and humans than ID or IE viruses.
• These are some of the known strains of mucambo virus that have been named based on their antigenic differences.

• The pathogenesis of the mucambo virus is the process by which it causes disease in its hosts. The virus known as Venezuelan equine encephalitis virus (VEEV) has a variant known as the Mucambo virus that is spread by mosquitoes that causes encephalomyelitis, also known as Venezuelan equine encephalitis (VEE). The pathogenesis of the mucambo virus depends on the host species, the viral subtype, and the route of infection.
• In humans, mucambo virus infection can occur through mosquito bites, contact with infected animals or their fluids or tissues, or inhalation of aerosolized virus. Once within the bloodstream, the virus can infect the liver, spleen, adrenal glands, lymph nodes, and other organs. The virus can also enter the central nervous system (CNS) and pass across the blood-brain barrier, damaging the brain and spinal cord and causing inflammation. The host’s immune status and the type of virus determine how severe the illness is. When a virus infects healthy adults, it can cause flu-like symptoms like headaches and high fevers. This condition can cause severe illness or death.
• If there are neurological symptoms, these may include photophobia, sleepiness, seizures, and confusion. It is more likely for children to experience long-term brain damage. Acute illness lasting four to six days may leave the patient frail for a few weeks.
• The pathogenesis of the mucambo virus is influenced by several factors, such as the viral strain, the host species and immune response, the route of infection, and the environmental conditions. Understanding the mucambo virus’s pathogenesis can help develop effective diagnosis, treatment, and prevention strategies for this disease.

• The host defenses against the mucambo virus are like those against other VEEV subtypes, and they involve both innate and adaptive immune responses.
• The innate immune response is the first line of defense against viral infections, and it consists of various cellular and molecular mechanisms that recognize and eliminate the invading pathogens. Some innate immune cells involved in the antiviral response are natural killer (NK) cells, macrophages, dendritic cells, and neutrophils. They can generate chemokines and cytokines that activate and recruit other immune cells and interferons (IFNs) that inhibit viral replication and induce an antiviral state in neighboring cells. Some of the innate immune molecules that can recognize viral components are:
• Toll-like receptors (TLRs).
• Like receptors for retinoic acid-inducible gene I (RIG-I) (RLRs).
• Antibiotics have the potential to upset the skin microbiome’s natural equilibrium.
• These receptors can trigger signaling pathways that activate Interferon regulatory factors (IRFs), and nuclear factor kappa B (NF-κB) are examples of transcription factors. The antiviral defense regulates the expression of genes linked to inflammation.
• The adaptive immune response is the second line of defense against viral infections, and it consists of specific and memory responses mediated by lymphocytes. The B cell and T cell are the two primary subtypes of lymphocytes. B cells can produce antibodies that bind to viral antigens and neutralize or opsonize them for phagocytosis by other immune cells. T cells are separated into helper T cells (Th) and cytotoxic T cells (Tc). The cells can help B cells for antibody production or secrete cytokines that modulate the immune response. Tc cells can kill infected cells by releasing perforin and granzymes or by expressing the Fas ligand that induces apoptosis.

• The symptoms of mucambo virus infection may vary depending on the host and the subtype of the virus. the Venezuelan equine encephalitis virus (VEEV) variant that infects humans is known as the mucambo virus. a virus spread by mosquitoes that results in encephalomyelitis or Venezuelan equine encephalitis (VEE). When a virus infects healthy adults, it can cause flu-like symptoms like headaches and high fevers. This condition can cause severe illness or death among young, old, or weakened immune systems.
• Seizures, sleepiness, confusion, and photophobia are examples of neurological symptoms that may be present. There is a higher chance of long-term brain damage in children. Following a 4–6 day acute sickness, the patient can experience weakness for a few weeks.

Diagnosis of Mucambo virus:

• Serology: Detecting antibodies in blood or CSF (ELISA, HI, CF, neutralization). Useful for past or recent infections, not early stages or immunocompromised patients.
• Molecular: Detecting viral nucleic acids using PCR, RT-PCR, qPCR, or sequencing. Rapid and sensitive, it requires specialized equipment and training.
• Isolation: Cultivating the virus in cell cultures, animals, or eggs. Definitive diagnosis, but time-consuming and biosafety risks.
• Antigen: Detecting viral proteins using IFA, IHC, or ICT. Rapid but lower sensitivity and specificity than molecular or serological methods.

Controls of mucambo virus:

• Vector control: Reduce mosquito populations and human-mosquito contact.
• Animal vaccination: Immunize susceptible equines to prevent spillover.
• Personal protection: Use repellents and protective clothing to minimize exposure.
• Surveillance: Monitor and report virus activity in humans and animals.
• Research: Generate scientific knowledge for prevention and control.

• Mucambo Virus – an overview | ScienceDirect Topics
• Isolation of Mucambo virus, a member of the Venezuelan equine encephalitis virus complex in the State of Sâo Paulo, Brasil. (cabdirect.org)